Infliximab therapy induces increased polyclonality of CD4+CD25+ regulatory T cells in psoriasis.
Diluvio
L
L
Romiti
M L
ML
Angelini
F
F
Campione
E
E
Rossi
P
P
Prinz
J C
JC
Chimenti
S
S
Lamioni
A
A
D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D015704:CD4 Antigens; D003879:Dermatologic Agents / Q000009:adverse effects*; D005260:Female; D006801:Humans; D000069285:Infliximab; D053645:Interleukin-2 Receptor alpha Subunit; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy*; D050378:T-Lymphocytes, Regulatory / Q000166:cytology / Q000187:drug effects*
D000911:Antibodies, Monoclonal; D015704:CD4 Antigens; D003879:Dermatologic Agents; D053645:Interleukin-2 Receptor alpha Subunit; D000069285:Infliximab